Skip to content
DraconiticResearch
Search Sources API
203,952 studies31 sourcesUpdated 24 min ago
Peer-reviewedCC BY 4.0Cancers

PET/MRI in Oncology: Real-World Recommendations

  • Ana María García-Vicente1,2
  • Lina García-Cañamaque3
  • José Ramón García-Garzón4
  • Montserrat Cortés-Romera5
  • David Durany-Lara6
  • Miguel Sebastián Casallas-Cepeda1
  • Stefanía Aida Guzmán-Ortiz1
  • Jaime Andrés Bonilla-Plaza1
  • Edel Noriega-Álvarez2,7
7 affiliations
  1. 1Nuclear Medicine Department, University Hospital of Toledo, 45007 Toledo, Spain
  2. 2Artificial Intelligence and Molecular Imaging Group, Instituto de Investigación Sanitaria de Castilla La Mancha (IDISCAM), 45071 Toledo, Spain
  3. 3Nuclear Medicine Department, Grupo Universitario HM Hospitales, 28050 Madrid, Spain
  4. 4Positron Emission Tomography Center Cetir Ascires, Viladomat, 08021 Barcelona, Spain
  5. 5Nuclear Medicine Department, Institute of Diagnostic Imaging (IDI), Hospital Universitario de Bellvitge, L’Hospitalet de Llobregat, 08907 Barcelona, Spain
  6. 6Department of Radiodiagnostics, Institute of Diagnostic Imaging (IDI), Germans Trias i Pujol University Hospital, 08916 Badalona, Spain
  7. 7Nuclear Medicine Department, University Hospital of Guadalajara, 45007 Toledo, Spain
Open at sourceDOICite

Abstract

Positron emission tomography/magnetic resonance imaging (PET/MRI) has represented a paradigm shift in medical imaging, and although its use has not yet been fully incorporated into all clinical guidelines, scientific evidence supports its ability to provide a highly accurate simultaneous metabolic and anatomical assessment, which is particularly useful for staging, treatment planning, and evaluating treatment response in cancer patients. The limited availability of the technique and the demands it places on resources and coordination suggest that its initial use should focus on those applications that can provide the greatest benefit to patients, especially within the indications related to oncological processes, where PET and MRI have a defined and complementary role. This review focuses specifically on some of these conditions.

Related

  1. Real‐world comprehensive care of people living with schizophrenia: recommendations across different settings and clinical stages
    Paolo Fusar‐Poli, Toby Pillinger, Robert Ali McCutcheon +32
    World PsychiatryPeer-reviewedLicence not stated12 citedPsychiatry & mental healthOpenAlex
  2. Clinical Translation of Artificial Intelligence in Oncology: Real-World Validation, Workflow Integration, and Precision Medicine Applications
    Ohmini Krishnamurthy Rajendran
    International Journal of Drug Delivery TechnologyPeer-reviewedLicence not statedFull text20 citedEpidemiology & public healthOpenAlex
  3. Precision immuno-oncology in triple-negative breast cancer: from PD-L1 to multimodal biomarkers, ADC–ICI combinations, and global real-world integration
    Jingna Wu
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textOncologyPMCCrossrefEurope PMC
  4. Real-World Evidence as a Driver of Precision Oncology and Personalized Therapeutic Sequencing in Later-Line Metastatic Colorectal Cancer
    Carlo Signorelli
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  5. HeCOG Cancer Biobank and Registry: a nationwide real-world resource for translational oncology research.
    E Fountzilas, K Papadopoulou, G-A Koliou +34
    ESMO real world data and digital oncologyPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{garciavicente2026petmri,
  title = {{PET/MRI in Oncology: Real-World Recommendations}},
  author = {Ana María García-Vicente and Lina García-Cañamaque and José Ramón García-Garzón and Montserrat Cortés-Romera and David Durany-Lara and Miguel Sebastián Casallas-Cepeda and Stefanía Aida Guzmán-Ortiz and Jaime Andrés Bonilla-Plaza and Edel Noriega-Álvarez},
  journal = {Cancers},
  year = {2026},
  month = nov,
  doi = {10.3390/cancers18213546},
  url = {https://www.mdpi.com/2072-6694/18/21/3546},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - PET/MRI in Oncology: Real-World Recommendations
AU  - Ana María García-Vicente
AU  - Lina García-Cañamaque
AU  - José Ramón García-Garzón
AU  - Montserrat Cortés-Romera
AU  - David Durany-Lara
AU  - Miguel Sebastián Casallas-Cepeda
AU  - Stefanía Aida Guzmán-Ortiz
AU  - Jaime Andrés Bonilla-Plaza
AU  - Edel Noriega-Álvarez
PY  - 2026
DA  - 2026/11/04
JO  - Cancers
DO  - 10.3390/cancers18213546
UR  - https://www.mdpi.com/2072-6694/18/21/3546
AB  - Positron emission tomography/magnetic resonance imaging (PET/MRI) has represented a paradigm shift in medical imaging, and although its use has not yet been fully incorporated into all clinical guidelines, scientific evidence supports its ability to provide a highly accurate simultaneous metabolic and anatomical assessment, which is particularly useful for staging, treatment planning, and evaluating treatment response in cancer patients. The limited availability of the technique and the demands it places on resources and coordination suggest that its initial use should focus on those applications that can provide the greatest benefit to patients, especially within the indications related to oncological processes, where PET and MRI have a defined and complementary role. This review focuses specifically on some of these conditions.
SN  - 2072-6694
ER  -